Gitterman Wealth Management LLC Takes Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Gitterman Wealth Management LLC acquired a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 621 shares of the medical research company’s stock, valued at approximately $204,000.

A number of other institutional investors also recently modified their holdings of BIO. Venturi Wealth Management LLC boosted its stake in shares of Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 87 shares during the last quarter. Gladius Capital Management LP acquired a new position in shares of Bio-Rad Laboratories during the 3rd quarter valued at $32,000. Picton Mahoney Asset Management lifted its position in shares of Bio-Rad Laboratories by 55.6% during the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 35 shares during the period. Asset Planning Inc acquired a new position in shares of Bio-Rad Laboratories during the 4th quarter valued at $33,000. Finally, UMB Bank n.a. lifted its position in shares of Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 32 shares during the period. 65.24% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. StockNews.com downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Royal Bank of Canada reiterated an “outperform” rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, Wells Fargo & Company dropped their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $395.20.

Bio-Rad Laboratories Stock Performance

BIO opened at $255.34 on Friday. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The company’s fifty day moving average price is $311.97 and its two-hundred day moving average price is $328.01. Bio-Rad Laboratories, Inc. has a 1-year low of $244.00 and a 1-year high of $387.99. The company has a market cap of $7.15 billion, a price-to-earnings ratio of -3.93 and a beta of 0.99.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. On average, analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.